The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Present at the Leerink Swann Cancer Roundtable Conference

Thursday, March 31, 2011

ARIAD to Present at the Leerink Swann Cancer Roundtable Conference07:35 EDT Thursday, March 31, 2011 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Swann Cancer Roundtable Conference being held at the Roosevelt Hotel in New York City, New York on Thursday, April 7, 2011. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company's strong oncology pipeline and progress on its three lead compounds at 3:30 p.m. (ET). Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD, will participate on a lymphoma and leukemia discussion panel at 2:15 p.m. (ET). Dr. Berger's presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for three weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit www.ariad.com. ARIAD Pharmaceuticals, Inc.Maria E. Cantor, 617-621-2208